Free tools Windows power users keep installed
One-click scans. No signup required.
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
No—CRISPR has not been shown to cure HIV in people. The most advanced HIV-targeted example identified here, EBT-101, is an experimental gene therapy studied in only six adults. A 2025 review reports that all three participants who temporarily stopped antiretroviral therapy (ART) under the study protocol experienced viral rebound. That is not ART-free control or a cure.
CRISPR remains a research strategy for attacking HIV that persists inside cells. It is not an approved treatment, and people with HIV should not stop, skip, or change ART because of gene-editing research.
What would “an HIV cure” have to achieve?
HIV is difficult to eradicate because some infected cells carry viral DNA integrated into their own chromosomes. ART can suppress production of new virus to an undetectable level, but it does not reliably remove every infected cell. If treatment is stopped, surviving infected cells can sometimes restart infection. A genuine cure claim would therefore need evidence that people remain free of clinically significant HIV without continuing ART, or that all replication-capable virus has been eliminated. A temporary laboratory measurement, a smaller reservoir, or a single person with an unusual response would not by itself establish a cure.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallOutdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchClinical trials are designed to test those questions in stages rather than to provide an experimental treatment on demand. NIH HIVinfo defines a clinical trial as “a research study in which people volunteer to help find answers to specific health questions.” The agency explains that investigational HIV interventions must be evaluated for safety and effectiveness before they could be considered for general use (NIH HIVinfo, reviewed September 16, 2025).
#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
How EBT-101 is intended to work
Targeting HIV DNA rather than treating symptoms
EBT-101 is an HIV-specific CRISPR/Cas9 system. Its intended job is to recognize HIV DNA integrated in infected cells and cut at selected viral sequences. In principle, cutting could disable viral genetic material or remove key sections so the cell can no longer produce infectious virus. This is different from ART, which blocks stages of the viral life cycle while medication is present.
Delivery with an AAV9 vector
The EBT-101 trial record describes intravenous delivery using an adeno-associated virus serotype 9 (AAV9) vector. The vector is a delivery vehicle for the gene-editing instructions; it is not itself an HIV medicine that patients can obtain by prescription. A one-time infusion also creates practical questions that researchers must answer, including which tissues receive enough editor, how long editing instructions persist, and whether unintended edits or immune reactions occur.
Who was studied and what the protocol asked
The Phase 1/2a study enrolled adults with aviremic HIV-1 infection—meaning virus suppressed on testing—who were taking stable ART. The protocol included an assessment for a possible analytical treatment interruption (ATI). An ATI is a planned pause in ART used to measure whether an investigational intervention controls virus without medication. It is conducted with clinical monitoring and predefined rules for restarting ART; it is not a recommendation for people outside the trial.
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
What the EBT-101 human evidence shows
The public registry is small and has no posted results
The ClinicalTrials.gov record for NCT05144386 lists six enrolled participants. The record was last updated December 2, 2024 and lists the study as completed on November 14, 2024, but the retrieved record contains no posted results. That means the registry alone provides study design and outcome measures, not a public efficacy analysis.
A 2025 review reports rebound in every ATI participant
A peer-reviewed 2025 review reports that EBT-101 was evaluated in six people with suppressed HIV and that three underwent an analytical treatment interruption. All three experienced viral rebound (“CRISPR/Cas9 for achieving postintervention HIV control,” 2025). On the evidence available in that review, the single dose did not produce ART-free HIV control in those participants.
That result is important, but it does not answer every future question. Six people cannot establish how often an intervention works across populations, and three ATI outcomes cannot determine whether a different dose, delivery system, viral target, treatment combination, or patient selection could perform differently. The evidence also does not establish a population-level efficacy percentage. It does establish that the cited early human experience is not a demonstrated cure.
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
Why viral rebound matters
When HIV becomes detectable again after ART is paused, it shows that replication-capable virus remained somewhere in the body or that the intervention did not control all relevant infected cells. For a cure-oriented therapy, rebound is a decisive clinical outcome: a person would need sustained control without ART, not merely a favorable laboratory result while medication continues.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errorsResearchers may still learn useful information from an ATI. Viral-load timing, the amount of virus after rebound, immune responses, and the point at which ART was restarted can help refine later studies. Those observations are investigational endpoints, not evidence that anyone should attempt an unsupervised interruption. Stopping ART can allow HIV to multiply, damage the immune system, and increase the risk of transmitting HIV.
CRISPR excision and CCR5 editing are different strategies
Gene-editing headlines often combine approaches that target completely different biological problems. EBT-101 aims at HIV DNA already inside infected cells. CCR5-editing programs instead alter a host-cell entry pathway so some immune cells are less susceptible to new HIV infection. Neither description makes the approaches interchangeable.
Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
| Approach | Primary target | How cells are reached | Human evidence described in the cited sources | What happened without ART |
|---|---|---|---|---|
| EBT-101 | Integrated HIV DNA | In-vivo intravenous AAV9 delivery of CRISPR/Cas9 instructions | Phase 1/2a study; six enrolled; registry had no posted results when last updated December 2, 2024 | A 2025 review reports rebound in all three participants who underwent ATI |
| SB-728-T | Host CCR5 in immune cells | Investigational modification of immune cells, not direct excision of HIV DNA | NIH describes it as an investigational therapy; CROI 2025 results cited by NIH found no greater reservoir reduction than unmodified T cells in the described comparison | NIH’s record notes partial viral-load control during an ATI, not a cure |
| 2014 CCR5 study | Host CCR5 in patients’ CD4 T cells | Cells modified outside the body with zinc-finger nucleases | Small, uncontrolled New England Journal of Medicine study; four evaluable participants for the HIV-RNA outcome | HIV RNA became undetectable in one of four evaluable participants; this was not a CRISPR study or a cure |
The NIH patient record for SB-728-T explains the investigational CCR5 strategy and its reported findings (NIH ClinicalInfo, “SB-728-T Patient Drug Record”). The cited CROI 2025 comparison also reported that CCR5-modified T cells did not reduce the HIV reservoir more than unmodified T cells in the described analysis. Partial viral-load control during an ATI is not the same as durable ART-free remission.
Why the 2014 zinc-finger result is not a CRISPR cure
An earlier study is sometimes presented as if it were evidence that gene editing has already cured HIV. The 2014 New England Journal of Medicine study used zinc-finger nucleases to modify each participant’s own CD4 T cells; it did not use CRISPR. In that small, uncontrolled study, HIV RNA became undetectable in one of four evaluable participants, and blood HIV DNA decreased in most participants. The authors concluded that the infusions were safe within the limits of that study.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Those findings are historical proof of concept for changing CCR5 in immune cells. They do not show that HIV was eradicated, that participants could permanently remain off ART, or that CRISPR excision works. The original report is available at NEJM, “Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV” (2014).
Best Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
Safety and limitations researchers still have to resolve
Early-stage gene therapy has risks beyond whether viral load falls. Investigators must monitor for immune reactions to the delivery vector or editor, effects on organs, unintended DNA changes, and whether enough relevant cells in blood and tissues are reached. An editor that cuts the intended HIV sequence may still fail if viral variants lack the target sequence or if infected cells are inaccessible. Cutting viral DNA also does not automatically remove every infected cell from the body.
The small EBT-101 enrollment limits what can be learned about uncommon adverse events. A study of six people cannot reliably estimate rare risks or compare outcomes among different ages, health conditions, HIV histories, or viral subtypes. The absence of posted registry results should not be interpreted as proof of either safety or harm; it means the public record retrieved for this article does not provide a complete results dataset.
Can someone stop ART after gene editing?
No. The ATI in the EBT-101 program was a research procedure with monitoring, not a self-care option. Anyone considering a change to ART should discuss it with an HIV clinician. Until a therapy has demonstrated durable control without medication in adequately designed studies and has received regulatory approval, ART remains the standard treatment context for people with HIV.
- Do not replace ART with a consumer “gene-editing” product, supplement, or unapproved infusion.
- Do not infer that an undetectable test while taking ART proves an infection has been removed.
- Do not enroll in an intervention without reviewing its consent form, monitoring plan, restart criteria, and known and unknown risks with the trial team.
- Ask whether a study is testing a CRISPR system against HIV DNA, a CCR5-editing strategy, or another intervention; the names describe different mechanisms.
How to assess future CRISPR-and-HIV headlines
New results may use words such as “reservoir reduction,” “functional cure,” “remission,” or “viral control.” These terms are not synonyms. Check the following details before treating a claim as a cure:
- Participants: How many people received the intervention, and how many were actually evaluated?
- ART status: Did participants remain suppressed on ART, or was there a monitored ATI? If ART was paused, how many rebounded and for how long?
- Endpoint: Was the result a change in HIV DNA, a viral-load measurement, a safety finding, or sustained control without ART?
- Follow-up: How long were participants observed? Short follow-up cannot establish durable remission.
- Study design: Was there a control group, and were the results published or only announced?
- Intervention identity: Does the therapy target integrated HIV DNA, alter CCR5, or use a different editing method such as zinc-finger nucleases?
- Regulatory status: Is it an investigational trial or an approved treatment available through ordinary HIV care?
Where the evidence stands now
The available human evidence supports cautious research, not a clinical cure. EBT-101 shows that an HIV-targeted CRISPR/Cas9 therapy can reach first-in-human testing, but its six-person study and the reported rebound in all three ATI participants do not demonstrate durable ART-free control. SB-728-T and the 2014 zinc-finger study address CCR5 rather than directly removing HIV DNA, and their findings cannot be relabeled as CRISPR cures.
Trial records and publications can change after the dates cited here. The EBT-101 registry’s last recorded update was December 2, 2024, while the human outcome summary comes from a 2025 review. Readers should check the current ClinicalTrials.gov entry and peer-reviewed publications for any later results, while treating claims of a present-day CRISPR cure as unproven unless durable, independently reported ART-free control is shown.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
